Gilead’s $4.3B liver bet; WuXi under fire; Exscientia CEO’s ouster; Late Friday cell therapy approval; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Next week will be a short­er week than usu­al for End­points be­cause we are ob­serv­ing Pres­i­dents’ Day on Mon­day. For any break­ing news, get in touch with Rey­nald Cas­tañe­da and our Lon­don crew at rcas­tane­da@end­pointsnews.com.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.